Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder.

Doctors looked back at 30 kids with autism who were given oxcarbazepine for irritability. They rated each child “much improved,” “minimally improved,” or “worse” from clinic notes. There was no pill placebo and no set dose.

About half of the children were called “much improved” by their doctors. One in four families stopped the drug because of side effects like tiredness or rash. The study is small and has no control group, so the numbers are soft.

Bhatti et al. (2013) used the exact same chart-review method with low-dose amitriptyline and saw a slightly higher success rate, hinting that oxcarbazepine is not clearly better. Deb et al. (2014) reviewed stronger RCT data for aripiprazole and still found frequent side-effects, showing this problem is not unique to oxcarbazepine. Hudson et al. (2012) scanned 33 drug trials and concluded only a few meds have solid proof in autism; oxcarbazepine is not on that short list.

If parents ask about oxcarbazepine for irritability, you can say it helped about half of kids in one small look-back study, but one in four quit because of side-effects. There is no strong evidence it beats safer options like behavioral plans or approved drugs. Use only when first-line meds fail, monitor closely, and document every change so the next clinician knows what was tried.